The FDA Accepts And Grants Priority Review To Astrazeneca's Supplemental Biologics License Application For Ultomiris (Ravulizumab) For Adults Patients With Immunoglobulin A Nephropathy; FDA Action Date Anticipated In Q4 Of 2026

뉴스 본문을 불러오고 있어요.

The FDA Accepts And Grants Priority Review To Astrazeneca's Supplemental Biologics License Application For Ultomiris (Ravulizumab) For Adults Patients With Immunoglobulin A Nephropathy; FDA Action Date Anticipated In Q4 Of 2026 | 웨이프 WAPE

The FDA Accepts And Grants Priority Review To Astrazeneca's Supplemental Biologics License Application For Ultomiris (Ravulizumab) For Adults Patients With Immunoglobulin A Nephropathy; FDA Action Date Anticipated In Q4 Of 2026

기사 요약

관련 종목

댓글 —